

FILE COPY

Please type a plus sign (+) inside this box →



#5 attach

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/938,853
		Filing Date	August 23, 2001
		First Named Inventor	ROSS
		Group Art Unit	1647
		Examiner Name	To Be Assigned
Sheet 1 of 2	Attorney Docket Number	UCAL082CON	

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
CA		4,670,393		Seeburg	06/02/1987	RECEIVED APR 03 2002 TECH CENTER 1600/2900
		5,019,400		Gombotz, et al.	05/25/1991	
		5,595,882		Fujisawa, et al.	01/21/1997	
CA		5,610,134		Clark, et al.	03/11/1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
CA			WO 90/04788			05/03/1990		
			WO 92/09690			06/11/1992		
			WO 94/12158			06/09/1994		
			WO 95/28173			10/26/1995		
			WO 96/40072			12/19/1996		
			WO 96/40256			12/19/1996		
			WO 96/40257			12/19/1996		
a			WO 96/40258			12/19/1996		

Examiner Signature	C. Saoud	Date Considered	9/22/03
--------------------	----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

APR 01 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number 09/938,853

Filing Date August 23, 2001

First Named Inventor ROSS

Group Art Unit 1647

Examiner Name To Be Assigned

Attorney Docket Number UCAL082CON

RECEIVED

TECH CENTER 1600/2900

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
OK		DUERR, R., ET AL., 1995, "Insulin-like Growth Factor-1 Enhances Ventricular Hypertrophy and Function during the Onset of Experimental Cardiac Failure," <i>J. Clin. Invest.</i> 95:619-27	
		DUERR, R., ET AL., 1996, "Cardiovascular Effects of Insulin-like Growth Factor-1 and Growth Hormone in Chronic Left Ventricular Failure in the Rat," <i>Circulation</i> 93: 2188-96.	
		FAZIO, S. ET AL., 1996, "A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy," <i>New Engl. J. Med.</i> 334:809-14.	
		JIN, H. ET AL., 1995, "Beneficial Effects of Growth Hormone and Insulin-like Growth Factor-1 in Experimental Heart Failure in Rats Treated with Chronic ACE Inhibition," <i>J. Cardiovasc. Pharmacol.</i> 26: 420-5.	
		SCHIEFFER, B. ET AL., 1994, "Comparative Effects of Chronic Angiotensin-Converting Enzyme Inhibition and Angiotensin Type 1 Receptor Blockade on Cardiac Remodeling After Myocardial Infarction in the Rat," <i>Circulation</i> 89: 2273-82.	
		WONG, P.C. ET AL., 1992, "Angiotensin II Receptor Antagonists and Receptor Subtypes," <i>Trends Endocrinol. Metab.</i> 3:211-7.	
		YANG, R. ET AL., 1995, "Growth Hormone Improves Cardiac Performance in Experimental Heart Failure," <i>Circulation</i> 92: 262-7.	
		DUERR, R., ET AL., "Cardiovascular Effects of Insulin-Like Growth Factor-1 and Growth Hormone in Chronic Left Ventricular Failure in the Rat", <i>Circulation</i> , (June 15, 1996), Vol. 93(12):2188-2196.	
		HONGO, M. ET AL., "Angiotensin II Blockade Followed by Growth Hormone as Adjunctive Therapy After Experimental Myocardial Infarction", <i>Journal of Cardiac Failure</i> , (September 1998), Vol. 4(3):213-224.	
		OSTERZIEL, M. ET AL., "Randomised, Double-blind, Placebo-controlled Trial of Human Recombinant Growth Hormone in Patients with Chronic Heart Failure due to Dilated Cardiomyopathy", <i>The Lancet</i> , (April 25, 1998), Vol. 351:1233-1237.	
CS		ROSS, JOHN ET AL., "The Role of Hypertrophy and Growth Factors in Heart Failure", <i>Journal of Cardiac Failure</i> , (December 1996), Vol. 2(4S):S121-S128.	

Examiner
Signature

C. Saouq

Date

Considered

9/22/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.